Optoceutics ApS - CVR: 39769689

2022, DKK

05.07.2023

Bruttoresultat

4.263'

Primær drift

Na.

Årets resultat

-3.636'

Aktiver

29.926'

Kortfristede aktiver

12.684'

Egenkapital

16.943'

Afkastningsgrad

0 %

Soliditetsgrad

57 %

Likviditetsgrad

438 %

Resultat

05.07.2023

Årsrapport	2022 05.07.2023	2021 18.07.2022	2020 06.07.2021	2018 10.09.2020
Nettoomsætning
Bruttoresultat	4.262.725	-2.177.118	-131.718	889.327
Resultat af primær drift	0	-5.417.711	-952.574	823.430
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0
Finansielle indtægter	11.812	74	0	0
Finansieringsomkostninger	-1.007.933	-68.559	-77.166	-1.390
Andre finansielle omkostninger	0	0	0	0
Resultat før skat	-5.051.935	-5.486.196	-1.029.740	822.040
Resultat	-3.635.660	-3.880.378	-506.333	652.067
Forslag til udbytte	0	0	0	0

Aktiver

05.07.2023

Årsrapport	2022 05.07.2023	2021 18.07.2022	2020 06.07.2021	2018 10.09.2020
Kortfristede varebeholdninger	1.733.355	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.073.799	1.382.342	1.369.784	884.563
Likvider	9.876.816	11.913.989	17.058.107	1.987.555
Kortfristede aktiver	12.683.970	13.296.331	18.427.891	2.872.118
Immaterielle aktiver og goodwill	16.760.276	12.874.137	8.786.599	0
Finansielle anlægsaktiver	0	275.659	0	0
Materielle aktiver	0	0	0	0
Langfristede aktiver	17.241.949	13.149.796	8.841.307	3.721.843
Aktiver	29.925.919	26.446.127	27.269.198	6.593.961

Aktiver

05.07.2023

Passiver

05.07.2023

Årsrapport	2022 05.07.2023	2021 18.07.2022	2020 06.07.2021	2018 10.09.2020
Forslag til udbytte	0	0	0	0
Egenkapital	16.943.109	13.367.310	16.247.893	5.051.729
Hensatte forpligtelser	0	1.009.253	1.280.130	811.589
Langfristet gæld til banker	0	0	0	0
Anden langfristet gæld	0	0	245.595	0
Leverandører af varer og tjenesteydelser	222.151	87.369	223.871	39.813
Kortfristede forpligtelser	2.898.157	3.569.564	995.580	730.643
Gældsforpligtelser	0	12.069.564	9.741.175	730.643
Forpligtelser	0	12.069.564	9.741.175	730.643
Passiver	29.925.919	26.446.127	27.269.198	6.593.961

Passiver

05.07.2023

Nøgletal

05.07.2023

Årsrapport	2022 05.07.2023	2021 18.07.2022	2020 06.07.2021	2018 10.09.2020
Afkastningsgrad	Na.	-20,5 %	-3,5 %	12,5 %
Dækningsgrad	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-21,5 %	-29,0 %	-3,1 %	12,9 %
Payout-ratio	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	-7.902,3 %	-1.234,4 %	59.239,6 %
Soliditestgrad	56,6 %	50,5 %	59,6 %	76,6 %
Likviditetsgrad	437,7 %	372,5 %	1.851,0 %	393,1 %

Resultat

05.07.2023

Gæld

05.07.2023

Årsrapport

05.07.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 05.07.2023)

Beretning

05.07.2023

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today discussed and approved the annual report for Optoceutics ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Principal activitiesAs of 2021 and 2022, OptoCeutics has constantly been working towards our long-term vision of building a technology platform for multiple neurological and psychiatric diseases with electrophysiological deficits such as anxiety, depression, ADHD, Alzheimer’s and dementia. Basing our technology platform on a product portfolio with the creation of new disease-modifying treatment options for neurological and psychiatric diseases, Optoceutics is advancing the world towards a state in which these diseases can be better understood, prevented, and ultimately treated, thereby benefiting not only patients, families, and healthcare providers. In the past year and half, Optoceutics has executed and finalized key business objectives within, but not limited to, medical device development, publications in leading medical journals within the field of Alzheimer's disease, clinical development, management of existing and filing of new intellectual property manufacturing processes, and business development. OptoCeutics has also officially launched the sales of our devices as a class 1 medical device in the EU. Finally, we have also initiated the launch of our devices for sale in the US with the submission of an FCC mark of our devices as a general wellness product. While our focus remains in the prevention and treatment of neurological disorders such as Alzheimer’s disease, we understand that healthy aging and early prevention is important for the pathology of later in life Alzheimer’s disease. Therefore, our ability to conduct real world experience and provide our devices to the general public will not only act as a foundation and establish OptoCeutics as the leaders in the brain stimulation market but also allow OptoCeutics to gain valuable insights into our user needs and data that will allow us to extend our impact beyond Alzheimer’s disease.